AngioLab, Inc.
KKRX:2512802,490.00
KRW
+290.00
(+13.18%)
ISIN
KR7251280004
Return %
Stock
S&P 500
1Y
-34.47
14.39
3Y
-68.84
81.42
5Y
-77.77
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Min-Yeong Kim
- Full Time Employees
- 15
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Daejeon South Korea
- IPO Date
- Oct 25, 2016
- Website
- angiolab.co.kr
- Similar Companies
- Business
- AngioLab, Inc. is a South Korea-based biopharmaceutical company specializing in the discovery, development, and commercialization of angiogenesis-inhibiting therapeutics, functional health food ingredients, and cosmeceuticals. Founded in 1999 and headquartered in Daejeon, South Korea, the company leverages proprietary natural product screening and matrix metalloproteinase (MMP) inhibition technologies to address vascular and metabolic disorders. AngioLab operates primarily across two business segments: Therapeutics Research and Development, and Functional Health Foods. The company's therapeutic pipeline comprises AL101-NASH, an oral herbal extract-based drug candidate under clinical development for non-alcoholic steatohepatitis (NASH/MASH); AL101-AMD and AL102-DME, angiogenesis-inhibiting therapeutic candidates in Phase 2 clinical trials for wet age-related macular degeneration and diabetic macular edema; AL101-PD, a therapeutic candidate targeting periodontal disease through collagenase and MMP inhibition; AL101-CIN, a candidate for cervical intraepithelial neoplasia; and preclinical programs targeting cancer metastasis and inflammatory arthritis. In its commercial health products division, the company manufactures and distributes proprietary raw materials and finished dietary supplements, headlined by Ob-X, a clinically validated and individually recognized functional ingredient formulated from lemon balm, Morus alba, and Artemisia capillaris extracts for visceral fat reduction; along with functional formulations for skin elasticity, metabolic wellness, and periodontal care. AngioLab distributes its products across South Korea and exports raw functional ingredients and consumer products to global markets throughout Asia, North America, and Europe through business-to-business supply agreements and distribution partnerships. In recent developments, AngioLab has progressed its clinical programs through Phase 2 evaluations for its NASH, wet AMD, and periodontal disease pipelines; expanded global supply and licensing agreements for its Ob-X functional ingredient; formed strategic research and commercialization alliances with domestic pharmaceutical firms; and advanced preparatory initiatives aimed at securing a technology evaluation-based transfer listing from the Korea New Exchange (KONEX) to the KOSDAQ market.